ProShare Advisors LLC Lowers Position in Insulet Corporation $PODD

ProShare Advisors LLC trimmed its position in Insulet Corporation (NASDAQ:PODD) by 20.3% during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 12,476 shares of the medical instruments supplier’s stock after selling 3,181 shares during the period. ProShare Advisors LLC’s holdings in Insulet were worth $3,852,000 at the end of the most recent reporting period.

A number of other institutional investors have also added to or reduced their stakes in the company. True Wealth Design LLC grew its position in shares of Insulet by 288.0% in the 3rd quarter. True Wealth Design LLC now owns 97 shares of the medical instruments supplier’s stock worth $30,000 after buying an additional 72 shares during the period. Golden State Wealth Management LLC lifted its position in Insulet by 202.9% during the 2nd quarter. Golden State Wealth Management LLC now owns 103 shares of the medical instruments supplier’s stock valued at $32,000 after acquiring an additional 69 shares during the period. Whittier Trust Co. of Nevada Inc. boosted its stake in Insulet by 48.9% during the third quarter. Whittier Trust Co. of Nevada Inc. now owns 131 shares of the medical instruments supplier’s stock worth $40,000 after acquiring an additional 43 shares in the last quarter. Quent Capital LLC purchased a new stake in Insulet in the third quarter worth about $49,000. Finally, Osterweis Capital Management Inc. bought a new position in shares of Insulet during the second quarter valued at approximately $51,000.

Wall Street Analysts Forecast Growth

A number of analysts have recently commented on the company. Barclays boosted their price target on Insulet from $300.00 to $301.00 and gave the stock an “equal weight” rating in a research report on Wednesday, November 5th. Jefferies Financial Group increased their target price on Insulet from $375.00 to $400.00 and gave the stock a “buy” rating in a research note on Thursday, November 6th. Stifel Nicolaus lowered their price target on Insulet from $370.00 to $350.00 and set a “buy” rating for the company in a research report on Wednesday, February 4th. BTIG Research upped their price target on shares of Insulet from $370.00 to $380.00 and gave the stock a “buy” rating in a research note on Friday, November 21st. Finally, Zacks Research lowered shares of Insulet from a “strong-buy” rating to a “hold” rating in a research note on Monday, January 5th. Twenty equities research analysts have rated the stock with a Buy rating and four have given a Hold rating to the stock. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus price target of $374.10.

Insulet Stock Up 0.8%

Shares of Insulet stock opened at $242.74 on Friday. Insulet Corporation has a twelve month low of $230.05 and a twelve month high of $354.88. The company has a quick ratio of 2.18, a current ratio of 2.87 and a debt-to-equity ratio of 0.68. The company’s 50 day moving average is $277.19 and its 200 day moving average is $306.27. The company has a market cap of $17.08 billion, a price-to-earnings ratio of 70.36, a price-to-earnings-growth ratio of 1.36 and a beta of 1.41.

About Insulet

Insulet Corporation is a medical device company headquartered in Acton, Massachusetts, that develops, manufactures and sells insulin-delivery systems for people with diabetes. The company’s core business is the design and commercialization of its Omnipod family of tubeless, wearable insulin pumps and the consumable Pods that deliver insulin. Insulet’s products aim to simplify insulin delivery for people with type 1 diabetes and insulin-requiring type 2 diabetes by offering an alternative to traditional insulin pens and tethered pump systems.

The company’s product portfolio includes the Omnipod System line—disposable, waterproof Pods that adhere to the skin and deliver insulin—and the associated controllers and mobile applications used to program and monitor insulin delivery.